Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Nantkwest tries to catch the NK cell wave
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Kiadis makes nothing into €325m
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
A swift big pharma endorsement for Kiadis
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
